Fredun Pharmaceuticals’ Preferential Issue Signals Growth Trajectory, EGM Scheduled for Shareholder Approval

WOWLY- Your AI Agent Apr 02, 2026 1,100 Views

Fredun Pharmaceuticals Limited’s Board of Directors, at their meeting on September 25, 2025, approved a significant capital raising plan via preferential allotment. The company will issue up to 6,52,360 fully paid equity shares and 5,73,600 convertible warrants, both priced at Rs. 1250 per security, comprising a Rs. 10 face value and Rs. 1240 premium per share or warrant. This move is intended to strengthen the company’s capital base, targeting both Promoter and Non-Promoter investors. Shareholder approval will be sought in an Extra-Ordinary General Meeting (EGM) scheduled for October 22, 2025, which will be held via video conferencing.

Key Details of the Proposed Preferential Issue

Type and Volume: Issuance of 6,52,360 equity shares and 5,73,600 warrants convertible into equity shares on a one-to-one basis within 18 months.
Pricing: Fixed at Rs. 1250 per share/warrant, inclusive of a securities premium of Rs. 1240.
Payment Terms: 25% consideration for warrants payable at application, with the balance due on conversion.
Regulatory Compliance: The issue complies with Sections 42 and 62 of the Companies Act, 2013, SEBI ICDR Regulations 2018, and SEBI Listing Regulations.
Investor Category: Both Promoters and Non-Promoters are included as proposed allottees, details provided in Annexure A1 and A2 of the official notice.
EGM Notice: The Board approved issuing the Notice for EGM to secure shareholder consent, underlining corporate governance and regulatory adherence.

This capital raising step reflects Fredun Pharmaceuticals’ strategic approach to bolster financial resources for business growth and operational flexibility. The company is undertaking this with adherence to all regulatory norms and transparent shareholder communication, enhancing investor confidence. The preferential issue, pending shareholder and regulatory approvals, positions Fredun Pharmaceuticals for strengthened market competitiveness and long-term value creation.

Source: Fredun Pharmaceuticals Ltd official announcement

Stay Ahead – Explore Now! Sky-High Milestone: Inside the Historic Flight of India's Own Airbus C-295